NASDAQConsumer StaplesAgricultural InputsSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for RKDA yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Use capital to support growth and shareholder value | A supporting condition in ARCADIA BIOSCIENCES INC's published investment case. The stated target is Effective use of $4 million capital to support growth by end 2026. | Under Pressure | Capital raised is not used effectively to support growth | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 6, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, speculative growth business, not an established durable compounder. The long-term thesis is on watch: Zola sales and cost control show some execution, while recent momentum and financial performance have weakened.
The evidence describes RKDA as cheap versus peers, but model confidence is low and the expectations gap is negative. The valuation label alone does not show that the market has fully accounted for losses, volatile management, weak results, or listing-rule notices.
Near term, Zola’s sales growth and new product plans support progress, and the company raised capital for working needs. Cost control is less clear: SG&A reached historic lows in the first half, but that priority is marked behind, and the elevated risk of an earnings miss and recent delisting notices add uncertainty.
The multi-year view hinges on whether Zola can sustain growth through product launches while the company manages costs and working capital. A guidance cut or continued weakening in jobs data would add pressure; strong results and higher guidance from sector leaders could support the sector backdrop.
Over the next 1 to 3 years, RKDA has a credible growth initiative but a fragile financial setup, with the thesis still dependent on execution and near-term results. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| These steps could help fix losses and improve value. |
| Broken |
| Net loss worsens beyond -$4.4 million next quarters |
Net income: $-6.266M FY2026-Q2; GAAP. Published target: Net loss improves toward -$1.3 million or better by 2026-Q4. The stored target says 2026-Q4; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 13, 2026-6,266,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue growth to support financial improvement | A primary condition in ARCADIA BIOSCIENCES INC's published investment case. The stated target is >= $1.1 million next quarter. | Intact | Revenue falls below $1.1 million next quarter | Revenue: $1.443M FY2026-Q2; GAAP. Published target: >= $1.1 million next quarter. The target does not explicitly identify fiscal versus calendar quarters. Aug 13, 20261,443,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.